These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23434135)

  • 1. Novel antiobesity agents: synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21.
    Alvarado M; Decara J; Luque MJ; Hernandez-Folgado L; Gómez-Cañas M; Gómez-Ruiz M; Fernández-Ruiz J; Elguero J; Jagerovic N; Serrano A; Goya P; de Fonseca FR
    Bioorg Med Chem; 2013 Apr; 21(7):1708-16. PubMed ID: 23434135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiobesity designed multiple ligands: Synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents.
    Alvarado M; Goya P; Macías-González M; Pavón FJ; Serrano A; Jagerovic N; Elguero J; Gutiérrez-Rodríguez A; García-Granda S; Suardíaz M; Rodríguez de Fonseca F
    Bioorg Med Chem; 2008 Dec; 16(23):10098-105. PubMed ID: 18952442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
    Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Fong TM; Shen CP; Lao J; Xiao JC; Shearman LP; Stribling DS; Rosko K; Strack A; Marsh DJ; Feng Y; Kumar S; Samuel K; Yin W; Van der Ploeg LH; Goulet MT; Hagmann WK
    J Med Chem; 2006 Dec; 49(26):7584-7. PubMed ID: 17181138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier.
    Receveur JM; Murray A; Linget JM; Nørregaard PK; Cooper M; Bjurling E; Nielsen PA; Högberg T
    Bioorg Med Chem Lett; 2010 Jan; 20(2):453-7. PubMed ID: 20015647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.
    Lee SH; Seo HJ; Kim MJ; Kang SY; Song KS; Lee SH; Jung ME; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1899-902. PubMed ID: 19269817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
    Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
    J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural analogs of pyrazole and sulfonamide cannabinoids: effects on acute food intake in mice.
    Wiley JL; Marusich JA; Zhang Y; Fulp A; Maitra R; Thomas BF; Mahadevan A
    Eur J Pharmacol; 2012 Nov; 695(1-3):62-70. PubMed ID: 22975289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and pharmacological evaluation of novel 4-alkyl-5-thien-2'-yl pyrazole carboxamides.
    Lazzari P; Pau A; Tambaro S; Asproni B; Ruiu S; Pinna G; Mastinu A; Curzu MM; Reali R; Bottazzi ME; Pinna GA; Murineddu G
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):254-76. PubMed ID: 22931442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
    Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
    J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives.
    Smith RA; Fathi Z; Brown SE; Choi S; Fan J; Jenkins S; Kluender HC; Konkar A; Lavoie R; Mays R; Natoli J; O'Connor SJ; Ortiz AA; Podlogar B; Taing C; Tomlinson S; Tritto T; Zhang Z
    Bioorg Med Chem Lett; 2007 Feb; 17(3):673-8. PubMed ID: 17107792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model.
    Srivastava BK; Joharapurkar A; Raval S; Patel JZ; Soni R; Raval P; Gite A; Goswami A; Sadhwani N; Gandhi N; Patel H; Mishra B; Solanki M; Pandey B; Jain MR; Patel PR
    J Med Chem; 2007 Nov; 50(24):5951-66. PubMed ID: 17979261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.
    Seo HJ; Kim MJ; Lee SH; Lee SH; Jung ME; Kim MS; Ahn K; Kim J; Lee J
    Bioorg Med Chem; 2010 Feb; 18(3):1149-62. PubMed ID: 20045337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: an effective scaffold for the design of either CB1 or CB2 receptor ligands.
    Piscitelli F; Ligresti A; La Regina G; Gatti V; Brizzi A; Pasquini S; Allarà M; Carai MA; Novellino E; Colombo G; Di Marzo V; Corelli F; Silvestri R
    Eur J Med Chem; 2011 Nov; 46(11):5641-53. PubMed ID: 21996466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Fubinaca/Rimonabant hybrids as endocannabinoid system modulators.
    Stefanucci A; Macedonio G; Dvorácskó S; Tömböly C; Mollica A
    Amino Acids; 2018 Nov; 50(11):1595-1605. PubMed ID: 30145711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential modulation of endogenous cannabinoid CB1 and CB2 receptors in spontaneous and splice variants of ghrelin-induced food intake in conscious rats.
    Ting CH; Chi CW; Li CP; Chen CY
    Nutrition; 2015 Jan; 31(1):230-5. PubMed ID: 25466669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists.
    Kang SY; Lee SH; Seo HJ; Jung ME; Ahn K; Kim J; Lee J
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2385-9. PubMed ID: 18337096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rimonabant Sanofi-Synthélabo.
    Fernandez JR; Allison DB
    Curr Opin Investig Drugs; 2004 Apr; 5(4):430-5. PubMed ID: 15134285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors.
    Reggio PH
    Curr Pharm Des; 2003; 9(20):1607-33. PubMed ID: 12871061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
    Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
    Doggrell SA
    Expert Opin Pharmacother; 2005 Oct; 6(12):2141-4. PubMed ID: 16197364
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.